Compare GSK plc (GSK) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard High Dividend Yield ETF — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while Vanguard High Dividend Yield ETF trades at $160.63. The key difference: GSK plc pays a 3.49% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | VYM | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $161.17 |
52-Week Low | $36.20 | $132.90 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Vanguard High Dividend Yield ETF (VYM) trades at $160.62, showing modest daily gains with bullish technical signals from moving averages. The ETF maintains broad diversification across 618 U.S. large-cap dividend payers with an ultra-low 0.04% expense ratio. Recent financial media coverage highlights VYM's role in retirement income strategies, comparing it favorably to peers like SCHD and HDV for its balance of yield and cost efficiency.
VYM presents a core holding for income-focused investors seeking diversified exposure to high-yield U.S. equities. The primary opportunity lies in its consistent dividend distributions and low-cost structure, while risks include interest rate sensitivity and potential underperformance during growth-dominated market cycles. Current technical positioning suggests near-term support around $159-160 with resistance at $161.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
